

Thyroid stimulating hormone in thyroid cancer: does it matter?

Nieto, Hannah; Boelaert, Kristien

DOI:
[10.1530/ERC-16-0328](https://doi.org/10.1530/ERC-16-0328)

License:
None: All rights reserved

Document Version
Peer reviewed version

Citation for published version (Harvard):
Nieto, H & Boelaert, K 2016, 'Thyroid stimulating hormone in thyroid cancer: does it matter?', *Endocrine-related cancer*, vol. 23, no. 11, ERC-16-0328. <https://doi.org/10.1530/ERC-16-0328>

[Link to publication on Research at Birmingham portal](#)

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Endocrine related cancer review

Thyroid stimulating hormone in thyroid cancer: does it matter?

Hannah Nieto¹ and Kristien Boelaert¹

¹Institute of Metabolism and Systems Research, University of Birmingham, Edgbaston,
Birmingham B15 2TT

Corresponding author: Dr Kristien Boelaert

Tel: +44 (0) 121 414 7400

Email: k.boelaert@bham.ac.uk

Postal address: Institute of Metabolism and Systems Research, 2nd floor IBR, University of
Birmingham, Edgbaston, Birmingham B15 2TT

Key words: TSH, thyroid cancer, nodules, suppression, prediction

Word count: 5,359

Serum TSH in thyroid cancer: does it matter?

Abstract

Differentiated thyroid cancer is the most common endocrine malignancy and the incidence is increasing rapidly worldwide. Appropriate diagnosis and post-treatment monitoring of patients with thyroid tumours is critical. Fine needle aspiration cytology remains the gold standard for diagnosing thyroid cancer and whilst there have been significant refinements to this technique, diagnostic surgery is often required for patients suspected to have malignancy. Serum thyroid stimulating hormone (TSH) is higher in patients with malignant thyroid nodules compared to those with benign disease, and TSH is proportionally increased in more aggressive tumours. Importantly, we have shown that the pre-operative serum TSH concentration independently predicts the presence of malignancy in subjects presenting with thyroid nodules. Establishing the use of TSH measurements in algorithms identifying high risk thyroid nodules in routine clinical practice represents an exciting, cost-efficient and non-invasive approach to optimise thyroid cancer diagnosis. Binding of TSH to receptors on thyrocytes stimulates a number of growth promoting pathways both in normal and malignant thyroid cells and TSH suppression with high doses of levothyroxine is routinely used following thyroidectomy in order to prevent cancer recurrence, especially in high risk tumours. This review examines the relationship between serum TSH and thyroid cancer and reflects on the clinical potential of TSH measurements in diagnosis and disease monitoring.

TSH in thyroid cancer: does it matter?

Introduction

Differentiated thyroid malignancy is the most common endocrine malignancy and over the last few decades, its incidence has increased dramatically worldwide (Kitahara and Sosa 2016; Sipos and Mazzaferri 2010). It is currently the fifth most common malignancy in women in the US and an estimated 62,000 new cases were found in North American men and women in 2015 (American Cancer Society 2015). Thyroid cancer causes more deaths than any other endocrine cancer (Monson 2000) and there will be an estimated 1,980 deaths from thyroid cancer in the US in 2016 (American Cancer Society 2016). The reasons for the observed increase in incidence have been widely debated (Wartofsky 2010) and include enhanced detection of subclinical thyroid cancer due to the growing use of diagnostic imaging as well as exposure to a number of environmental factors (Kitahara and Sosa 2016). Whilst better access to health care in countries with high socio-economic status may in part explain the rising incidence, observations of increased thyroid cancer rates in lower socio-economic countries, an increasing number of larger tumours as well as the changing thyroid cancer molecular profiles indicate that other factors are likely to be involved (Vigneri, et al. 2015). A number of disease modifiable factors including obesity have been identified as potential aetiological factors (Schmid, et al. 2015). Moreover a variety of thyroid-specific environmental carcinogens have been implicated including ionising radiation, increased dietary iodine intake and environmental pollutants (Vigneri et al. 2015). Overall, the observed changes in thyroid cancer incidence are likely due to a combination of detection bias and true increases in incidence.

Thyroid cancer often presents as a solitary nodule or as a part of a multinodular goitre. This creates an important clinical dilemma as thyroid nodules are very common occurring in 50-67% of the population and more than 90% are benign (Durante, et al. 2015; Hegedus 2004; Mazzaferri 1992; Popoveniuc and Jonklaas 2012). Detection rates of thyroid nodules are increasing due to widespread use of imaging modalities in advanced health care systems (Cramer, et al. 2010; Popoveniuc and

Jonklaas 2012). While incidental thyroid neoplasms have long been recognised due to their presence during post-mortem examinations (Dean and Gharib 2008), there is a significant and increasing clinical burden associated with detecting this disease in patients (Brito, et al. 2014), for whom the differentiation between aggressive and indolent diagnoses is crucial (Cabanillas, et al. 2016a).

There are a number of well-established and evolving clinical tools to discern malignant from benign thyroid nodules (He, et al. 2016). Most international guidelines recommend the use of a combination of diagnostic tools, including measurement of thyroid stimulating hormone (TSH) to assess functional thyroid status, high resolution ultrasonography (US) scanning to assess the morphological characteristics of the thyroid and nodule(s), and fine needle aspiration biopsy for cytological evaluation of the presence of malignancy (Hegedus, et al. 2003; Perros, et al. 2014; Pitoia and Miyauchi 2015). In recent years the use of panels of molecular markers to refine the cytological diagnosis of malignancy has received significant attention, although these tests are very expensive and not used routinely in all centres (Xing, et al. 2013). Since most benign nodules do not require further intervention it is pertinent that thyroid malignancy is diagnosed accurately and further refinement of current diagnostic approaches is required.

If malignancy is diagnosed, surgery is the primary treatment modality for differentiated thyroid cancer, followed by adjuvant radioiodine ablative therapy in a significant number of patients (Burns and Zeiger 2010; Perros et al. 2014; Pitoia and Miyauchi 2015). Since TSH is a growth factor for thyroid cells, therapy with suppressive doses of levothyroxine is often used postoperatively and this has long been known to positively affect outcomes in differentiated thyroid cancer (Mazzaferri and Jhiang 1994; McLeod, et al. 2012; Pujol, et al. 1996). Current guidelines recommend the medium to long term use of TSH suppression in high risk thyroid cancer but not in lower risk tumours because of the health risks associated with the induction of subclinical and overt thyrotoxicosis (Perros et al. 2014; Pitoia and Miyauchi 2015).

89 The diagnosis and post-therapy monitoring of patients with thyroid nodules and cancer is
90 important. We were the first to publish that serum TSH is raised in patients with malignant thyroid
91 nodules compared to those with benign disease (Boelaert et al 2006), and subsequent studies have
92 shown that pre-operative serum TSH is proportionally higher in those with more aggressive disease
93 (Boelaert, et al. 2006; Figuera, et al. 2015; Haymart, et al. 2009; Jonklaas, et al. 2008; McLeod, et al.
94 2014). This review aims to explore the relationship between TSH and thyroid cancer, both before
95 and after a diagnosis of malignancy is made.

Thyroid-stimulating hormone

Hormone structure and biochemical details

Thyroid stimulating hormone (TSH) is a two subunit glycoprotein, released from the pituitary gland in response to hypothalamic release of thyrotropin releasing hormone (TRH). The alpha subunit of the glycoprotein is similar to that of luteinising hormone (LH) and follicle-stimulating hormone (FSH), with specificity only related to the beta subunit. TSH, or thyrotropin, stimulates the thyroid to produce and secrete thyroxine (T4) and triiodothyronine (T3). The released T4 becomes effective once converted peripherally to triiodothyronine (T3) by deiodinase enzymes. The functionally active circulating hormones provide a feedback loop directly to both the hypothalamus and the pituitary suppressing further release of TSH and TRH, thereby maintaining homeostatic control of the hypothalamic-pituitary-thyroid axis (Magner 1989; Sarapura, et al. 2011; Szkudlinski, et al. 2002).

TSH function in the normal thyroid

TSH acts on thyroid cells signalling through the TSH receptor, which is found predominantly on follicular thyroid cells. TSH is a growth factor for thyrocytes, with prolonged exposure causing hyperplasia and hypertrophy (Sarapura et al. 2011). Stimulation of the TSH receptor causes activation of the adenylate cyclase pathway, resulting in alterations in cell-cycle proteins causing changes in thyroid gland growth and cell morphology, as well as the production of thyroid hormones. The effects of TSH can be broadly summarised as follows: synthesis of thyroid hormones, thyroid gland growth, changes in thyrocyte morphology, regulation of post-transcriptional activation of the sodium iodide symporter (NIS) and modulating extra-thyroidal effects (Sarapura et al. 2011).

Diagnosing thyroid malignancy

Types of thyroid cancer

Thyroid cancers arise from thyroid follicular cells or parafollicular cells. Differentiated thyroid cancer (DTC) includes two subtypes, papillary and follicular cancers, both of which arise from

follicular cells and together make up 90% of thyroid cancers. Papillary thyroid cancers are the most common and represent 85% of all thyroid malignancies. Medullary thyroid cancers account for 3-4% of all thyroid cancers and 80% arise from sporadic mutations, whereas the remainder are hereditary, usually as part of multiple endocrine neoplasia syndromes. Finally, thyroid cancers can be undifferentiated, referred to as anaplastic thyroid cancers, and these tumours have the most aggressive phenotype and the worst prognosis with median survival rates of 3-7 months (Cabanillas, et al. 2016b).

Current diagnostic approaches and limitations

Guidelines recommend that patients suspected to have thyroid malignancy are assessed by a physician with a specialist interest in thyroid cancer care, and who is a regular member of the multi-disciplinary team (Perros et al. 2014). It is paramount to perform a full clinical assessment which includes taking a personal and family history as well as careful clinical examination (Hegedus 2004; Hegedus et al. 2003; Perros et al. 2014; Pitoia and Miyauchi 2015). In many cases, however, thyroid glands harboring malignancy are clinically indistinguishable from those that do not and there is substantial variation among practitioners in evaluating nodules. Features suggestive of malignancy include the presence of firm, fixed thyroid lumps, vocal cord palsy, a positive family history, rapid nodule growth and being at the extremities of age (>60 years or <20 years) (Hegedus et al. 2003). Table 1 displays clinical characteristics associated with an increased risk of malignancy.

The serum TSH concentration is routinely measured to exclude the presence of a toxic nodule causing subclinical or overt hyperthyroidism in all patients (Hegedus et al. 2003; Perros et al. 2014; Pitoia and Miyauchi 2015). If the TSH is below the laboratory reference range, assays for free triiodothyronine (fT3) and free thyroxine (fT4) are required in order to exclude overt hyperthyroidism (raised free T4 and free T3) or “T3-toxicosis” (raised serum free T3 alone). Similarly, if TSH is raised then overt hypothyroidism must be excluded (this being indicated by low fT4 with a raised TSH concentration). Although virtually all patients with thyroid carcinoma are euthyroid, the

presence of a suppressed serum thyrotrophin (TSH) level (generally indicative of subclinical or overt thyrotoxicosis) does not rule out the presence of malignancy (Hegedus 2004; Hegedus et al. 2003; Perros et al. 2014; Pitoia and Miyauchi 2015). Measurement of serum thyroglobulin is of little value in the initial diagnosis of thyroid cancer whereas this remains an important tumor marker in the follow-up of patients with thyroid cancer (Perros et al. 2014; Pitoia and Miyauchi 2015). Measurements of basal plasma calcitonin and carcino-embryonic antigen (CEA) are useful if medullary carcinoma is suspected but do not form part of the routine evaluation of thyroid nodules (Perros et al. 2014).

Thyroid ultrasonography is an extremely sensitive tool for the diagnosis of thyroid nodules and may be specific in diagnosing papillary thyroid cancer (Cesur, et al. 2006; Hambly, et al. 2011). Moreover this imaging modality aids the decision-making processes of which nodules to target for fine needle aspiration biopsy (FNAB) and increases the diagnostic yield of thyroid cell sampling (American Cancer Society 2015; Perros et al. 2014; Pitoia and Miyauchi 2015). Multiple studies have confirmed typical sonographic features associated with increased risks of malignancy (Table 2(Frates, et al. 2005; Hambly et al. 2011; Lee, et al. 2011)) and current guidelines now recommend the use of a combination of these features in algorithms predicting the likelihood of thyroid malignancy as well as the selection of nodules requiring (FNAB) (Haugen, et al. 2015; Perros et al. 2014; Pitoia and Miyauchi 2015). High resolution ultrasonography by an experienced operator is highly recommended in the initial evaluation of patients with thyroid nodules.

Fine needle aspiration cytology remains the gold standard to confirm absence or presence of thyroid malignancy. The results can confirm that a nodule is benign, triage patients requiring diagnostic surgery or confirm a diagnosis of malignancy enabling one step therapeutic surgery (Perros et al. 2014; Pitoia and Miyauchi 2015). In the UK, cytology results are reported using the THY classification (The Royal College of Pathologists 2009) whereas in the US the Bethesda scoring system (Bongiovanni, et al. 2012) is employed. Despite accuracy of diagnosis in the majority of thyroid nodules, FNAC has drawbacks including the sometimes high rate of insufficient/inadequate

samples, the inability to distinguish between benign and malignant follicular lesions and difficulties in detecting follicular variant papillary carcinomas (Rago, et al. 2007; Sangalli, et al. 2006).

Indeterminate or suspicious thyroid lesions represent 10-26% of nodules evaluated cytologically. These nodules usually require diagnostic surgery and a median 34% of patients with indeterminate nodules have thyroid malignancy (Xing et al. 2013). In order to avoid unnecessary thyroidectomy, a number of centres use gene expression classifiers or mutation analysis panels to further refine the cytological diagnosis. These diagnostic tools however are very expensive and only routinely available in a limited number of centers world-wide (Bernet, et al. 2014; Pitoia and Miyauchi 2015). Whilst there have been significant advances in our current diagnostic approaches for thyroid cancer, further cost-efficient and easily applicable approaches are needed to allow informed decision making for both physicians and patients when evaluating the likelihood of malignancy in thyroid nodules.

Serum TSH in the diagnosis of thyroid cancer

TSH and promotion of thyroid cancer growth

Several studies including two large meta-analyses (McLeod et al. 2012; Zheng, et al. 2016) have confirmed that higher serum TSH is associated with an increased risk of differentiated thyroid cancer. Table 3 demonstrates a range of original research studies investigating the link between serum TSH concentrations and differentiated thyroid cancer. Importantly, several studies have shown higher TSH to predict thyroid malignancy, independent of other risk factors including patients' age and gender as well as a positive family history (Kim, et al. 2013; McLeod et al. 2012). The first study was performed by our group, and demonstrated an increase in risk of diagnosis of malignancy in parallel with an increase in serum TSH (Boelaert et al. 2006). The lowest risk of thyroid cancer diagnosis was in those with a TSH below the lower limit of the reference range (<0.4 mIU/l). There was a significant cut off at serum TSH of 0.9mIU/l, with an increased risk of cancer diagnosis in those with serum TSH concentrations above this. The highest risk of cancer diagnosis was in the

group with subclinical hypothyroidism who had serum TSH >5.5. mIU/l. Importantly we found that, even within the normal range, higher TSH concentrations correlate with a higher risk of DTC and this was subsequently confirmed by others (Haymart, et al. 2008).

Higher pre-operative serum TSH concentrations have also been associated with more advanced cancer stage at diagnosis. Mean serum TSH levels were higher in those with stage III and IV disease and in those with larger tumours or in cancers associated with lymph node metastases (Fiore, et al. 2009; Haymart et al. 2008; Shi, et al. 2016). A meta-analysis of 28 studies, analysing 42,032 control subjects and 5,786 patients with thyroid cancers has confirmed that higher pre-operative TSH levels are associated with increased risk of thyroid malignancy as well as a correlation with higher disease grade (McLeod et al. 2012). A more recent meta-analysis of 56 studies encompassing 20,227 thyroid cancer cases and 50,003 controls with benign thyroid nodules has confirmed that higher serum TSH level were significantly associated with thyroid cancer size and with the presence of lymph node metastasis (Zheng et al. 2016). These findings are consistent with serum TSH having a role in the promotion of thyroid tumour growth and aggressiveness.

Indeed TSH is a known growth factor for thyroid nodules and suppression of serum TSH concentrations by administering exogenous thyroid hormone may inhibit the growth of established nodules as well as the development of new nodules (Papini, et al. 1998). Benign and malignant thyroid tumours express functional TSH receptors on the plasma membrane (Ichikawa, et al. 1976) and TSH increases adenylate cyclase activity leading to cAMP production and cell growth through stimulation of these receptors in vitro (Carayon, et al. 1980). Importantly the expression of TSH receptors in DTC has been associated with an improved prognosis (Shi, et al. 1993). Differentiated thyroid cancers usually retain responsiveness to TSH and suppressive doses of levothyroxine can be used to inhibit the progression of metastatic thyroid cancer (Simpson, et al. 1988) as well as decrease rates of recurrence in patients treated with surgery or radioactive iodine (Biondi, et al. 2005; McGriff, et al. 2002), in keeping with TSH's tropic effect on thyroid tissue promoting neoplasia and carcinogenesis.

TSH and the initiation of thyroid cancer

It has been demonstrated that even in patients who do not present with thyroid nodules, higher serum TSH concentrations are associated with increased risks of thyroid malignancy. In a large sample drawn from the general population TSH levels were significantly higher in patients with DTC when compared with the control group. Among 1,548 controls, 606 subjects had thyroid nodules detected on ultrasound. Further subgroup analysis demonstrated that control subjects without detectable thyroid nodules had proportionally higher risks of DTC as TSH concentration rose, suggesting a role for TSH in the generation of thyroid cancer. This study did not indicate a relationship between higher serum TSH concentrations and more advanced thyroid cancer in contrast with others (Fiore et al. 2009; Haymart et al. 2008; McLeod et al. 2012; Zheng et al. 2016).

Evidence for a role of TSH in the development of thyroid tumours comes from studies of the TR $\beta^{PV/PV}$ mouse which has a dominant negative mutant thyroid hormone nuclear receptor gene inserted in the TR β locus. This mouse model has disrupted pituitary-thyroid axis signalling resulting in raised serum TSH concentrations and the rapid development of metastatic thyroid cancer (Suzuki, et al. 2002). Crossing of this model with TSH receptor gene knockout mice (TSHR $^{-/-}$) resulted in impaired thyroid growth and no occurrences of thyroid cancer, consistent with a role for TSH in thyroid tumourigenesis (Lu, et al. 2010).

Serum TSH and thyroid autoimmunity

Several studies have indicated an association between thyroid autoimmunity and thyroid malignancy (Boelaert 2009; Haymart et al. 2008; McLeod et al. 2012). There is an increased incidence of thyroid cancer in patients with Hashimoto's disease. Our previous study (Boelaert et al. 2006) demonstrated that although raised thyroid peroxidase (TPO) levels did not independently predict malignancy, patients with cancer had significantly higher levels of TPO antibody than patients with benign disease. Fiore et al. (Fiore et al. 2009) demonstrated that TSH was higher in patients independent of whether they had raised TPO antibodies or not, and that there was no difference in rates of thyroid carcinoma between the autoimmune thyroid disease population and

antibody negative patients. Haymart et al. (Haymart et al. 2008) observed the debate about association of thyroid cancer with both Hashimoto's disease and Graves' disease. They suggest that as Hashimoto's disease often progresses to hypothyroidism resulting in elevated TSH concentrations, and because Graves' disease is associated with TSH receptor stimulation, which is associated with thyroid cancer (Mazzaferri 2000), it follows that TSH receptor activation is the link between thyroid cancer and thyroid autoimmune disease. More recently, a study directed at assessment of anti-thyroglobulin antibody (TgAb) measured pre-operative levels in differentiated thyroid cancer patients and concluded that TgAb was not an independent predictor of DTC prognosis, once adjusted for age and gender (McLeod et al. 2014); they noted that TgAb may be raised in autoimmunity and in patients exhibiting an immune response to the tumour, and may not be a true representation of thyroid autoimmune disease. Figure 1 summarises the potential effects of TSH as a tumour initiator, cancer promoter or in relation to thyroid auto-immunity.

Aetiology of raised serum TSH concentrations in thyroid cancer

There is no consensus on why serum TSH is raised in differentiated thyroid cancer nor do we fully understand the cause and effect relationship (Boelaert 2009). Iodine deficiency causes a consequent rise in serum TSH concentrations and chronic iodine deficiency is a well-established risk factor for the development of goitre and follicular thyroid cancer (Feldt-Rasmussen 2001; Lind, et al. 1998; Nagataki and Nystrom 2002). However, a causal role for TSH in the initiation of thyroid cancer has not been exclusively demonstrated and it remains unclear if serum TSH concentrations are higher as a consequence of the presence of thyroid malignancy.

A further potential explanation is that patients with lower serum TSH concentrations already have or are progressing towards development of autonomously functioning thyroid nodules, which are less likely to be malignant (Hegedus 2004; Hegedus et al. 2003; Mann, et al. 1988). Fiore et al demonstrated significant age-dependent development of thyroid autonomy (serum TSH<0.4 mIU/l) in patients with benign thyroid disease but this was less evident in those with papillary thyroid cancer and in patients with multinodular goitre. The frequency of thyroid autonomy was higher and

the risk of papillary thyroid cancer was lower than in those with solitary nodules, consistent with a protective effect of lower serum TSH concentrations on thyroid cancer development or progression (Boelaert 2009; Fiore et al. 2009).

Serum TSH and papillary microcarcinoma

Papillary microcarcinomas, defined as thyroid cancer <10mm in diameter, are increasing dramatically in frequency, and distinguishing those that proliferate and progress aggressively from small indolent tumours is difficult. The increased incidence is partly due to the finding of incidentalomas on routine imaging as well as on histopathological examination of thyroid specimens removed for reasons not associated with the suspicion of malignancy (Roti, et al. 2008). Current guidelines do not recommend completion thyroidectomy nor the administration of radioiodine routinely for these tumours. A more conservative approach for their management has been recommended, and for low risk patients, who have isolated and intrathyroidal tumours, without nodal metastases, lobectomy is sufficient (Haugen et al. 2015; Pacini, et al. 2012; Perros et al. 2014). In those with evidence of metastases, a positive family history, previous radiation to the head and neck or in subjects older than 45 years, total thyroidectomy and radioiodine ablation may be indicated (Mazzaferri 2007; Perros et al. 2014; Pitoia and Miyauchi 2015).

Two main difficulties arise from these modern guidelines: (i) a subset of these tumours progress and metastasise (Page, et al. 2009; Roti, et al. 2006); (ii) patients, when presented with a cancer diagnosis, often prefer comprehensive therapy, which leaves them with the best prognosis and the lowest risk of recurrence, often despite the potential cost of any associated treatment morbidity. While current tumour staging systems are unable to guide therapy in papillary microcarcinomas, the potential for use of TSH to assist in assessing prognosis is appealing.

The association between raised serum TSH measurements and papillary thyroid microcarcinoma has been studied (Table 4), and some have suggested this as a means to estimate thyroid cancer risk in those with thyroid nodule of less than 1 cm in size (Moon, et al. 2012). However not all studies are consistent. Sohn, et al. (Sohn, et al. 2014) demonstrated the association

between higher TSH and risk of malignancy in tumours over 1cm, but not in papillary microcarcinomas. Similarly, an Italian study showed that TSH was not significantly different in thyroid papillary microcarinoma patients compared to their controls consisting of patients with negative histology (Negro, et al. 2013; Sohn et al. 2014). A meta-analysis of nine studies encompassing 6,523 subjects demonstrated that some smaller studies were biased due to heterogeneous controls, and overall confirmed a significant association between higher serum TSH and papillary microcarcinoma, supporting the hypothesis that TSH is involved in differentiated thyroid tumorigenesis. The authors stated that there is insufficient evidence to show that TSH is directly involved in thyroid carcinoma initiation but the data support the hypothesis that raised TSH is associated with risk of cancer and progression (Shi et al. 2016). At present, it is unclear how the increased detection of small indolent microcarcinomas influences the utility of using serum TSH in clinical decision algorithms.

Whether TSH is an important factor in disease initiation or progression remains unclear. An argument against its involvement in tumour initiation is the lack of TSH receptor mutations interfering with signal transduction in thyroid carcinomas (Matsuo, et al. 1993). Furthermore, thyroid carcinomas can occur in patients with a range of serum TSH, including in those who take exogenous thyroid hormones and have suppressed serum TSH concentrations for treatment of other thyroid diseases (Satta, et al. 1993).

On the contrary, a mouse-model with a knock-in of oncogenic BRAF generated by Franco et al. developed invasive thyroid carcinomas and concomitantly became profoundly hypothyroid as demonstrated by significantly raised TSH levels. Following knockout of the TSH receptor (to genetically replicate ablation of the TSH signalling pathway) there was a significant lag in the period before tumour formation, and the tumours that developed were much less aggressive (Franco, et al. 2011). These findings contribute to the idea that TSH per se may not be oncogenic independently, but raised concentrations are likely to contribute significantly to tumour development and progression.

328

329 ***Serum TSH and follicular thyroid cancer***

330 Follicular thyroid carcinomas provide a unique diagnostic challenge, in that they cannot be
331 diagnosed by cytological evaluation alone. While there may be factors indicating neoplastic change
332 in fine needle aspirates, follicular carcinoma is defined as a tumour that invades the capsule, a
333 feature that cannot be identified on cytological evaluation rendering these cancers indistinguishable
334 from thyroid adenomas using cytopathology. The standard treatment of choice is therefore
335 diagnostic hemithyroidectomy, which requires no further surgery in adenomatous lesions, but is
336 usually followed up by completion hemithyroidectomy, radioiodine ablation and suppression of TSH
337 in the majority of invasive follicular carcinomas (McHenry and Phitayakorn 2011; Perros et al. 2014;
338 Pitoia and Miyauchi 2015).

339 Raised serum TSH levels have been demonstrated in patients with follicular carcinoma
340 compared to those with benign follicular disease (Kunt, et al. 2015). While the TSH level is unlikely to
341 be the single factor in follicular thyroid cancer development, some have advocated using its
342 measurement in combination with other determinators of risk stratification, even to the point of
343 defining treatment, i.e. whether to proceed with hemithyroidectomy or not (Kuru, et al. 2009).
344 Despite the potential for the application of TSH measurements in the management of follicular
345 thyroid carcinomas, there is a paucity of studies addressing this specifically (Zheng et al. 2016).

346 ***TSH and non-differentiated thyroid cancer***

347 Due to the different pathophysiology of medullary thyroid cancer, TSH concentrations are
348 not implicated in the likelihood of diagnosis, nor in the follow up monitoring of these tumours.
349 Responsiveness of thyroid cancer to TSH depends on TSH receptor expression, and de-differentiated
350 cancers demonstrate significant reductions in expression of thyroid specific proteins including TSH
351 receptors, thyroid peroxidase and thyroglobulin (Brabant, et al. 1991; Sheils and Sweeney 1999).
352 Anaplastic thyroid cancers represent extreme forms of dedifferentiated tumours and these tumours
353 are characteristically very difficult to treat due to the lack of expression of proteins involved in the

thyroid machinery. Expression of the sodium iodide symporter is often absent, thereby significantly reducing the functional effectiveness of radioiodine ablation and treatment. Current therapeutic approaches include the re-differentiation of these tumours with various agents to improve treatability (Dong, et al. 2013; Kang, et al. 2011; Schmutzler and Kohrle 2000). In view of the inherent lack of expression of normal TSH receptors in anaplastic thyroid cancers, serum TSH concentrations have not been studied in relation to the diagnosis or progression of these tumours. It seems unlikely that finding of altered TSH levels in this context, would aid the choice of available treatment options nor would it affect the very poor prognosis associated with these rare thyroid cancers.

TSH in follow up of patients with thyroid malignancy

Until recently, the long term management of differentiated thyroid cancers included the suppression of serum TSH concentrations with supraphysiological concentrations of levothyroxine for extended periods of time, regardless of the tumour-specific risk stratification. Current guidelines recommend against TSH suppression into low risk tumours which have not been treated with radioiodine or those who are stratified in the excellent response categories following dynamic risk stratification (Haugen et al. 2015; Perros et al. 2014; Pitoia and Miyauchi 2015). For those tumours that have not undergone further risk stratification at 1-year post-treatment, current practice is to suppress TSH levels with exogenous thyroid hormone to less than 0.1 mU/l for 5-10 years post-treatment. At this point, depending on the clinical response, the TSH suppression can be relaxed (Perros et al. 2014). Some studies have indicated that TSH suppression may inhibit the generation of new thyroid nodules, as well as the growth and tumourigenic potential in existing nodules (Papini et al. 1998), although current guidelines do not recommend of thyroid hormone suppressive therapy in patients with thyroid nodules (Haugen et al. 2015; Perros et al. 2014; Pitoia and Miyauchi 2015).

TSH suppression in differentiated thyroid cancer follow-up

Suppressive serum TSH to very low level reduces the rates of thyroid cancer recurrence and has been shown to improve differentiated thyroid cancer patient outcomes. TSH is a growth factor for thyroid nodules, and it is considered that suppression of TSH can prevent new nodule formation as well as inhibition of current nodules (Papini et al. 1998). In the context of differentiated thyroid carcinoma treatment, after resection of thyroid carcinoma and radioiodine treatment, TSH suppression therapy positively affects cancer outcomes including disease-specific survival (Mazzaferri and Jhiang 1994), and reduces recurrence (Pujol et al. 1996). Therefore it is widely recommended that patients have TSH suppression after successful treatment in the early post-operative period (Haugen et al. 2015).

Risks associated with TSH suppression

Despite the widespread use of TSH suppression in patients who have been treated for differentiated thyroid cancer, this treatment approach is not completely without risk. Subclinical hyperthyroidism has been demonstrated to have significant deleterious health consequences. This includes a spectrum of cardiovascular risks, including atrial fibrillation and coronary heart disease morbidity and mortality (Collet, et al. 2012). There is also a documented association with dementia, decreased cognitive function (Annerbo and Lokk 2013) and osteoporosis (Biondi, et al. 2015; Polovina, et al. 2015).

Outcomes for high grade thyroid cancers have been improved with TSH suppression and some advocate the need for more aggressive suppression in higher stage disease (Jonklaas, et al. 2006). In view of the aforementioned risk factors associated with this approach, current guidelines (Perros et al. 2014) now recommend the use of tools including the FRAX score to determine bone health and fracture risk (Kanis, et al. 2008) in patients who are on suppressive therapy with levothyroxine for 5 years or longer during thyroid cancer follow-up. Overall an individualised approach combining assessment of the patient's response to treatment and risk of disease progression with an evaluation of the potential health risks associated with long term TSH

suppression is advised in establishing the required dose and length of course of levothyroxine therapy.

Conclusion

Patients presenting with a thyroid nodule or thyroid enlargement should have their serum TSH measured as part of the initial assessment. Following our paper in 2006 (Boelaert et al. 2006), a significant body of evidence has accumulated confirming the association between higher serum TSH concentrations and likelihood of thyroid cancer diagnosis. A recent meta-analysis demonstrated this relationship in thyroid tumours of all sizes, including papillary microcarcinomas in adult as well as in paediatric thyroid cancers (Zheng et al. 2016). Several studies and meta-analyses have also established a relationship between raised TSH levels and cancer progression, and increased concentrations were associated with advanced disease and lymph node metastasis (Fiore et al. 2009; McLeod et al. 2012; Zheng et al. 2016).

The diagnostic accuracy of serum TSH as a biochemical predictor of malignancy however has not yet been established and meta-analyses have failed to provide conclusive data to provide a single useful cut-off value to pass TSH as an independent and validated test (McLeod et al. 2012; Zheng et al. 2016) and measurement of this biochemical marker has not yet been incorporated into clinical decision algorithms. There have been suggestions that its measurement may be useful in combination with other tests including ultrasonography and fine needle aspiration cytology. At a time when thyroid nodules are increasingly being diagnosed, and whilst the differentiation between benign and malignant lesions remains difficult in a significant proportion of subjects, it is important to consider incorporating TSH levels into the stratification of patients' thyroid cancer risk.

Furthermore, treatment with TSH suppression in the follow-up of patients with thyroid cancer has been re-evaluated. There are significant long term health risks associated with TSH suppression and further refinement of the stratification approaches regarding the risk of disease progression or recurrence will help identify those patients in whom the risks of long-term

428 suppressive therapy outweigh the risks. Large prospective studies to evaluate this further will be of
429 utmost importance. Whilst there is little doubt that serum TSH is raised in differentiated thyroid
430 cancer, the full integration of this finding into clinical pathways relating to the diagnosis and
431 management of patients is yet to be undertaken.

435 **Declaration of interest**

436 The authors declare that there is no conflict of interest that could be perceived as prejudicing the
437 impartiality of the research reported.

438 **Funding**

439 This research did not receive any specific grant from any funding agency in the public, commercial or
440 not-for-profit sector.

441 **Author contributions**

442 Both authors were involved with the design, drafting and revision of the article, and have both
443 approved the final version.

444 **Acknowledgements**

445 Not applicable

447 **References**

- 448 American Cancer Society 2015 Cancer Facts and Figures. In *American Cancer Society*.
449 American Cancer Society 2016 Key statistics for thyroid cancer.
- 450 Annerbo S & Løkk J 2013 A clinical review of the association of thyroid stimulating hormone
451 and cognitive impairment. *ISRN Endocrinol* **2013** 856017.
- 452 Bernet V, Hupart KH, Parangi S & Woeber KA 2014 AACE/ACE disease state commentary:
453 molecular diagnostic testing of thyroid nodules with indeterminate cytopathology. *Endocr*
454 *Pract* **20** 360-363.
- 455 Biondi B, Bartalena L, Cooper DS, Hegedus L, Laurberg P & Kahaly GJ 2015 The 2015
456 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous
457 Subclinical Hyperthyroidism. *Eur Thyroid J* **4** 149-163.
- 458 Biondi B, Filetti S & Schlumberger M 2005 Thyroid-hormone therapy and thyroid cancer: a
459 reassessment. *Nat Clin Pract Endocrinol Metab* **1** 32-40.
- 460 Boelaert K 2009 The association between serum TSH concentration and thyroid cancer.
461 *Endocr Relat Cancer* **16** 1065-1072.
- 462 Boelaert K, Horacek J, Holder RL, Watkinson JC, Sheppard MC & Franklyn JA 2006 Serum
463 thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated
464 by fine-needle aspiration. *J Clin Endocrinol Metab* **91** 4295-4301.
- 465 Bongiovanni M, Spitale A, Faquin WC, Mazzucchelli L & Baloch ZW 2012 The Bethesda
466 System for Reporting Thyroid Cytopathology: a meta-analysis. *Acta Cytol* **56** 333-339.
- 467 Brabant G, Maenhaut C, Kohrle J, Scheumann G, Dralle H, Hoang-Vu C, Hesch RD, von zur
468 Muhlen A, Vassart G & Dumont JE 1991 Human thyrotropin receptor gene: expression in
469 thyroid tumors and correlation to markers of thyroid differentiation and dedifferentiation.
470 *Mol Cell Endocrinol* **82** R7-12.
- 471 Brito JP, Hay ID & Morris JC 2014 Low risk papillary thyroid cancer. *Bmj* **348** g3045.
- 472 Burns WR & Zeiger MA 2010 Differentiated thyroid cancer. *Semin Oncol* **37** 557-566.
- 473 Cabanillas ME, McFadden DG & Durante C 2016a Thyroid cancer. *Lancet*.
- 474 Cabanillas ME, Zafereo M, Gunn GB & Ferrarotto R 2016b Anaplastic Thyroid Carcinoma:
475 Treatment in the Age of Molecular Targeted Therapy. *J Oncol Pract* **12** 511-518.
- 476 Carayon P, Thomas-Morvan C, Castanas E & Tubiana M 1980 Human thyroid cancer:
477 membrane thyrotropin binding and adenylate cyclase activity. *J Clin Endocrinol Metab* **51**
478 915-920.
- 479 Cesur M, Corapcioglu D, Bulut S, Gursoy A, Yilmaz AE, Erdogan N & Kamel N 2006
480 Comparison of palpation-guided fine-needle aspiration biopsy to ultrasound-guided fine-
481 needle aspiration biopsy in the evaluation of thyroid nodules. *Thyroid* **16** 555-561.
- 482 Collet TH, Gussekloo J, Bauer DC, den Elzen WP, Cappola AR, Balmer P, Iervasi G, Asvold BO,
483 Sgarbi JA, Volzke H, et al. 2012 Subclinical hyperthyroidism and the risk of coronary heart
484 disease and mortality. *Arch Intern Med* **172** 799-809.
- 485 Cramer JD, Fu P, Harth KC, Margevicius S & Wilhelm SM 2010 Analysis of the rising incidence
486 of thyroid cancer using the Surveillance, Epidemiology and End Results national cancer data
487 registry. *Surgery* **148** 1147-1152; discussion 1152-1143.
- 488 Dean DS & Gharib H 2008 Epidemiology of thyroid nodules. *Best Pract Res Clin Endocrinol*
489 *Metab* **22** 901-911.

490 Dong JJ, Zhou Y, Liu YT, Zhang ZW, Zhou XJ, Wang HJ & Liao L 2013 In vitro evaluation of the
 491 therapeutic potential of nevirapine in treatment of human thyroid anaplastic carcinoma.
 492 *Mol Cell Endocrinol* **370** 113-118.
 493 Durante C, Costante G, Lucisano G, Bruno R, Meringolo D, Paciaroni A, Puxeddu E,
 494 Torlontano M, Tumino S, Attard M, et al. 2015 The natural history of benign thyroid
 495 nodules. *Jama* **313** 926-935.
 496 Feldt-Rasmussen U 2001 Iodine and cancer. *Thyroid* **11** 483-486.
 497 Figuera TM, Perez CL, Faris N, Scarabotto PC, da Silva TT, Cavalcanti TC, Mesa Junior CO,
 498 Miasaki F, da Paz Filho GJ & de Carvalho GA 2015 TSH levels are associated with increased
 499 risk of thyroid carcinoma in patients with nodular disease. *Endokrynol Pol* **66** 480-485.
 500 Fiore E, Rago T, Provenzale MA, Scutari M, Ugolini C, Basolo F, Di Coscio G, Berti P, Grasso L,
 501 Elisei R, et al. 2009 Lower levels of TSH are associated with a lower risk of papillary thyroid
 502 cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective
 503 role. *Endocr Relat Cancer* **16** 1251-1260.
 504 Franco AT, Malaguarnera R, Refetoff S, Liao XH, Lundsmith E, Kimura S, Pritchard C, Marais
 505 R, Davies TF, Weinstein LS, et al. 2011 Thyrotrophin receptor signaling dependence of Braf-
 506 induced thyroid tumor initiation in mice. *Proc Natl Acad Sci U S A* **108** 1615-1620.
 507 Frates MC, Benson CB, Charboneau JW, Cibas ES, Clark OH, Coleman BG, Cronan JJ, Doubilet
 508 PM, Evans DB, Goellner JR, et al. 2005 Management of thyroid nodules detected at US:
 509 Society of Radiologists in Ultrasound consensus conference statement. *Radiology* **237** 794-
 510 800.
 511 Gerschpacher M, Gobl C, Anderwald C, Gessl A & Krebs M 2010 Thyrotropin serum
 512 concentrations in patients with papillary thyroid microcancers. *Thyroid* **20** 389-392.
 513 Hambly NM, Gonen M, Gerst SR, Li D, Jia X, Mironov S, Sarasohn D, Fleming SE & Hann LE
 514 2011 Implementation of evidence-based guidelines for thyroid nodule biopsy: a model for
 515 establishment of practice standards. *AJR Am J Roentgenol* **196** 655-660.
 516 Haugen BRM, Alexander EK, Bible KC, Doherty G, Mandel SJ, Nikiforov YE, Pacini F, Randolph
 517 G, Sawka A, Schlumberger M, et al. 2015 2015 American Thyroid Association Management
 518 Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer.
 519 *Thyroid*.
 520 Haymart MR, Glinberg SL, Liu J, Sippel RS, Jaume JC & Chen H 2009 Higher serum TSH in
 521 thyroid cancer patients occurs independent of age and correlates with extrathyroidal
 522 extension. *Clin Endocrinol (Oxf)* **71** 434-439.
 523 Haymart MR, Repplinger DJ, Levenson GE, Elson DF, Sippel RS, Jaume JC & Chen H 2008
 524 Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated
 525 with greater risks of differentiated thyroid cancer and advanced tumor stage. *J Clin*
 526 *Endocrinol Metab* **93** 809-814.
 527 He LZ, Zeng TS, Pu L, Pan SX, Xia WF & Chen LL 2016 Thyroid Hormones, Autoantibodies,
 528 Ultrasonography, and Clinical Parameters for Predicting Thyroid Cancer. *Int J Endocrinol*
 529 **2016** 8215834.
 530 Hegedus L 2004 Clinical practice. The thyroid nodule. *N Engl J Med* **351** 1764-1771.
 531 Hegedus L, Bonnema SJ & Bennedbaek FN 2003 Management of simple nodular goiter:
 532 current status and future perspectives. *Endocr Rev* **24** 102-132.
 533 Ichikawa Y, Saito E, Abe Y, Homma M & Muraki T 1976 Presence of TSH receptor in thyroid
 534 neoplasms. *J Clin Endocrinol Metab* **42** 395-398.

535 Jiao J & Zhou Y 2015 [Relationship between serum thyroxin-stimulating hormone and
536 papillary thyroid micrcarcinoma in nodular thyroid disease]. *Zhonghua Yi Xue Za Zhi* **95** 908-
537 911.

538 Jonklaas J, Nsouli-Maktabi H & Soldin SJ 2008 Endogenous thyrotropin and triiodothyronine
539 concentrations in individuals with thyroid cancer. *Thyroid* **18** 943-952.

540 Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR,
541 Ladenson PW, Magner J, et al. 2006 Outcomes of patients with differentiated thyroid
542 carcinoma following initial therapy. *Thyroid* **16** 1229-1242.

543 Kang HJ, Youn YK, Hong MK & Kim LS 2011 Antiproliferation and Redifferentiation in Thyroid
544 Cancer Cell Lines by Polyphenol Phytochemicals. *J Korean Med Sci* **26** 893-899.

545 Kanis JA, Johnell O, Oden A, Johansson H & McCloskey E 2008 FRAX™ and the assessment of
546 fracture probability in men and women from the UK. *Osteoporos Int* **19** 385-397.

547 Khan MA, Khan KH, Shah SA, Mir KA, Khatkhat M & Shahzad MF 2016 Risk Factors Associated
548 with Thyroid Carcinoma in North Pakistan. *Asian Pac J Cancer Prev* **17** 377-380.

549 Kim HK, Yoon JH, Kim SJ, Cho JS, Kweon SS & Kang HC 2013 Higher TSH level is a risk factor
550 for differentiated thyroid cancer. *Clin Endocrinol (Oxf)* **78** 472-477.

551 Kitahara CM & Sosa JA 2016 The changing incidence of thyroid cancer. *Nat Rev Endocrinol*.
552 Kunt M, Cirit E, Eray IC, Yalay O, Parsak CK & Sakmann G 2015 Parameters predicting
553 follicular carcinoma in thyroid nodules with indeterminate cytology. *Ann Ital Chir* **86** 301-
554 306.

555 Kuru B, Gulcelik NE, Gulcelik MA & Dincer H 2009 Predictive index for carcinoma of thyroid
556 nodules and its integration with fine-needle aspiration cytology. *Head Neck* **31** 856-866.

557 Lee YH, Kim DW, In HS, Park JS, Kim SH, Eom JW, Kim B, Lee EJ & Rho MH 2011
558 Differentiation between Benign and Malignant Solid Thyroid Nodules Using an US
559 Classification System. *Korean J Radiol* **12** 559-567.

560 Lind P, Langsteger W, Molnar M, Gallowitsch HJ, Mikosch P & Gomez I 1998 Epidemiology of
561 thyroid diseases in iodine sufficiency. *Thyroid* **8** 1179-1183.

562 Lu C, Zhao L, Ying H, Willingham MC & Cheng SY 2010 Growth activation alone is not
563 sufficient to cause metastatic thyroid cancer in a mouse model of follicular thyroid
564 carcinoma. *Endocrinology* **151** 1929-1939.

565 Magner JA 1989 Thyroid-Stimulating Hormone: Structure and Function. In *Control of the*
566 *Thyroid Gland: Regulation of Its Normal Function and Growth*, pp 27-103. Eds R Ekholm, LD
567 Kohn & SH Wollman. Boston, MA: Springer US.

568 Mann K, Saller B, Mehl U, Hormann R & Moser E 1988 Highly sensitive determination of TSH
569 in the follow-up of TSH-suppressive therapy of patients with differentiated thyroid cancer.
570 *Nuklearmedizin* **27** 24-28.

571 Matsuo K, Friedman E, Gejman PV & Fagin JA 1993 The thyrotropin receptor (TSH-R) is not
572 an oncogene for thyroid tumors: structural studies of the TSH-R and the alpha-subunit of Gs
573 in human thyroid neoplasms. *J Clin Endocrinol Metab* **76** 1446-1451.

574 Mazzaferri EL 1992 Thyroid cancer in thyroid nodules: finding a needle in the haystack. *Am J*
575 *Med* **93** 359-362.

576 Mazzaferri EL 2000 Thyroid cancer and Graves' disease: the controversy ten years later.
577 *Endocr Pract* **6** 221-225.

578 Mazzaferri EL 2007 Management of low-risk differentiated thyroid cancer. *Endocr Pract* **13**
579 498-512.

580 Mazzaferri EL & Jhiang SM 1994 Long-term impact of initial surgical and medical therapy on
581 papillary and follicular thyroid cancer. *Am J Med* **97** 418-428.

582 McGriff NJ, Csako G, Gourgiotis L, Lori CG, Pucino F & Sarlis NJ 2002 Effects of thyroid
583 hormone suppression therapy on adverse clinical outcomes in thyroid cancer. *Ann Med* **34**
584 554-564.

585 McHenry CR & Phitayakorn R 2011 Follicular Adenoma and Carcinoma of the Thyroid Gland.
586 *Oncologist* **16** 585-593.

587 McLeod DS, Cooper DS, Ladenson PW, Ain KB, Brierley JD, Fein HG, Haugen BR, Jonklaas J,
588 Magner J, Ross DS, et al. 2014 Prognosis of differentiated thyroid cancer in relation to serum
589 thyrotropin and thyroglobulin antibody status at time of diagnosis. *Thyroid* **24** 35-42.

590 McLeod DS, Watters KF, Carpenter AD, Ladenson PW, Cooper DS & Ding EL 2012
591 Thyrotropin and thyroid cancer diagnosis: a systematic review and dose-response meta-
592 analysis. *J Clin Endocrinol Metab* **97** 2682-2692.

593 Monson JP 2000 The epidemiology of endocrine tumours. *Endocr Relat Cancer* **7** 29-36.

594 Moon SS, Lee YS, Lee IK & Kim JG 2012 Serum thyrotropin as a risk factor for thyroid
595 malignancy in euthyroid subjects with thyroid micronodule. *Head Neck* **34** 949-952.

596 Nagataki S & Nystrom E 2002 Epidemiology and primary prevention of thyroid cancer.
597 *Thyroid* **12** 889-896.

598 Negro R, Valcavi R, Riganti F, Toulis KA, Colosimo E, Bongiovanni M, Grassi P, Giovanella L,
599 Gardini G & Piana S 2013 Thyrotropin values in patients with micropapillary thyroid cancer
600 versus benign nodular disease. *Endocr Pract* **19** 651-655.

601 Pacini F, Castagna MG, Brilli L & Pentheroudakis G 2012 Thyroid cancer: ESMO Clinical
602 Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* **23** Suppl 7 vii110-119.

603 Page C, Biet A, Boute P, Cuvelier P & Strunski V 2009 'Aggressive papillary' thyroid
604 microcarcinoma. *Eur Arch Otorhinolaryngol* **266** 1959-1963.

605 Papini E, Petrucci L, Guglielmi R, Panunzi C, Rinaldi R, Bacci V, Crescenzi A, Nardi F, Fabbri
606 R & Pacella CM 1998 Long-term changes in nodular goiter: a 5-year prospective randomized
607 trial of levothyroxine suppressive therapy for benign cold thyroid nodules. *J Clin Endocrinol*
608 *Metab* **83** 780-783.

609 Perros P, Boelaert K, Colley S, Evans C, Evans RM, Gerrard Ba G, Gilbert J, Harrison B,
610 Johnson SJ, Giles TE, et al. 2014 Guidelines for the management of thyroid cancer. *Clinical*
611 *Endocrinology* **81** 1-122.

612 Pitoia F & Miyauchi A 2015 2015 American Thyroid Association Guidelines for Thyroid
613 Nodules and Differentiated Thyroid Cancer and Their Implementation in Various Care
614 Settings. *Thyroid*.

615 Polovina S, Micic D, Miljic D, Milic N, Micic D & Popovic V 2015 The Fracture Risk
616 Assessment Tool (FRAX score) in subclinical hyperthyroidism. *Vojnosanit Pregl* **72** 510-516.

617 Polyzos SA, Kita M, Efstathiadou Z, Poulakos P, Slavakis A, Sofianou D, Flaris N, Leontsini M,
618 Kourtis A & Avramidis A 2008 Serum thyrotropin concentration as a biochemical predictor of
619 thyroid malignancy in patients presenting with thyroid nodules. *J Cancer Res Clin Oncol* **134**
620 953-960.

621 Popoveniuc G & Jonklaas J 2012 Thyroid nodules. *Med Clin North Am* **96** 329-349.

622 Pujol P, Daures JP, Nsakala N, Baldet L, Bringer J & Jaffiol C 1996 Degree of thyrotropin
623 suppression as a prognostic determinant in differentiated thyroid cancer. *J Clin Endocrinol*
624 *Metab* **81** 4318-4323.

625 Rago T, Di Coscio G, Basolo F, Scutari M, Elisei R, Berti P, Miccoli P, Romani R, Faviana P,
626 Pinchera A, et al. 2007 Combined clinical, thyroid ultrasound and cytological features help to
627 predict thyroid malignancy in follicular and Hürthle cell thyroid lesions: results from a
628 series of 505 consecutive patients. *Clin Endocrinol (Oxf)* **66** 13-20.

629 Roti E, degli Uberti EC, Bondanelli M & Braverman LE 2008 Thyroid papillary
630 microcarcinoma: a descriptive and meta-analysis study. *Eur J Endocrinol* **159** 659-673.

631 Roti E, Rossi R, Trasforini G, Bertelli F, Ambrosio MR, Busutti L, Pearce EN, Braverman LE &
632 Degli Uberti EC 2006 Clinical and histological characteristics of papillary thyroid
633 microcarcinoma: results of a retrospective study in 243 patients. *J Clin Endocrinol Metab* **91**
634 2171-2178.

635 Sangalli G, Serio G, Zampatti C, Bellotti M & Lomuscio G 2006 Fine needle aspiration
636 cytology of the thyroid: a comparison of 5469 cytological and final histological diagnoses.
637 *Cytopathology* **17** 245-250.

638 Sarapura VD, Gordon DF & Samuels MH 2011 Chapter 6 - Thyroid-stimulating Hormone A2 -
639 Melmed, Shlomo. In *The Pituitary (Third Edition)*, pp 167-203. San Diego: Academic Press.

640 Satta MA, De Rosa G, Testa A, Maussier ML, Valenza V, Rabitti C, Saletnich I, D'Ugo D &
641 Picciocchi A 1993 Thyroid cancer in suppressed contralateral lobe of patients with hot
642 thyroid nodule. *Eur J Cancer* **29a** 1190-1192.

643 Schmid D, Ricci C, Behrens G & Leitzmann MF 2015 Adiposity and risk of thyroid cancer: a
644 systematic review and meta-analysis. *Obes Rev* **16** 1042-1054.

645 Schmutzler C & Kohrle J 2000 Retinoic acid redifferentiation therapy for thyroid cancer.
646 *Thyroid* **10** 393-406.

647 Sheils OM & Sweeney EC 1999 TSH receptor status of thyroid neoplasms--TaqMan RT-PCR
648 analysis of archival material. *J Pathol* **188** 87-92.

649 Shi L, Li Y, Guan H, Li C, Shi L, Shan Z & Teng W 2012 Usefulness of serum thyrotropin for risk
650 prediction of differentiated thyroid cancers does not apply to microcarcinomas: results of
651 1,870 Chinese patients with thyroid nodules. *Endocr J* **59** 973-980.

652 Shi RL, Liao T, Qu N, Liang F, Chen JY & Ji QH 2016 The Usefulness of Preoperative Thyroid-
653 Stimulating Hormone for Predicting Differentiated Thyroid Microcarcinoma. *Otolaryngol*
654 *Head Neck Surg* **154** 256-262.

655 Shi Y, Zou M & Farid NR 1993 Expression of thyrotrophin receptor gene in thyroid carcinoma
656 is associated with a good prognosis. *Clin Endocrinol (Oxf)* **39** 269-274.

657 Simpson WJ, Panzarella T, Carruthers JS, Gospodarowicz MK & Sutcliffe SB 1988 Papillary
658 and follicular thyroid cancer: impact of treatment in 1578 patients. *Int J Radiat Oncol Biol*
659 *Phys* **14** 1063-1075.

660 Sipos JA & Mazzaferri EL 2010 Thyroid cancer epidemiology and prognostic variables. *Clin*
661 *Oncol (R Coll Radiol)* **22** 395-404.

662 Sohn SY, Kim HJ, Jang HW, Kim SW & Chung JH 2014 Lack of association between high serum
663 thyroid-stimulating hormone level and risk of papillary thyroid microcarcinomas. *Head Neck*
664 **36** 43-46.

665 Suzuki H, Willingham MC & Cheng SY 2002 Mice with a mutation in the thyroid hormone
666 receptor beta gene spontaneously develop thyroid carcinoma: a mouse model of thyroid
667 carcinogenesis. *Thyroid* **12** 963-969.

668 Szkudlinski MW, Fremont V, Ronin C & Weintraub BD 2002 Thyroid-stimulating hormone
669 and thyroid-stimulating hormone receptor structure-function relationships. *Physiol Rev* **82**
670 473-502.

671 The Royal College of Pathologists 2009 Guidance on the Reporting of Thyroid Cytology
672 Specimens.
673 Vigneri R, Malandrino P & Vigneri P 2015 The changing epidemiology of thyroid cancer: why
674 is incidence increasing? *Curr Opin Oncol* **27** 1-7.
675 Wartofsky L 2010 Increasing world incidence of thyroid cancer: increased detection or
676 higher radiation exposure? *Hormones (Athens)* **9** 103-108.
677 Xing M, Haugen BR & Schlumberger M 2013 Progress in molecular-based management of
678 differentiated thyroid cancer. *Lancet* **381** 1058-1069.
679 Zafon C, Obiols G, Baena JA, Castellvi J, Dalama B & Mesa J 2012 Preoperative thyrotropin
680 serum concentrations gradually increase from benign thyroid nodules to papillary thyroid
681 microcarcinomas then to papillary thyroid cancers of larger size. *J Thyroid Res* **2012** 530721.
682 Zheng J, Li C, Lu W, Wang C & Ai Z 2016 Quantitative assessment of preoperative serum
683 thyrotropin level and thyroid cancer. *Oncotarget*.

684

685

Figure Legend

Figure illustrating TSH binding to its receptor in normal thyroid physiology. Potential roles of high serum TSH concentrations in the initiation and progression of thyroid carcinogenesis as well as putative links with thyroid autoimmunity in the context of contributing environmental and genetic factors are indicated.

706 **Table 1: Clinical features suggestive of thyroid malignancy (Hegedus 2004; Popoveniuc and**
707 **Jonklaas 2012)**

708

History	Physical examination
Family Hx of MEN, MTC, PTC	Firm nodule 709
History of head and neck irradiation as child or adolescent	Nodule fixed to adjacent structures 710
History of Hodgkin and non-Hodgkin lymphoma and irradiation	Growth of nodules, especially during therapy to suppress TSH 711
Age < 20	Abnormal cervical lymph nodes 712
Age > 70	Vocal cord paralysis
Male gender	713
Symptoms of compression: hoarseness, dysphagia, dyspnoea, cough, dysphonia	714

715

716 **Table 2: US features associated with thyroid malignancy. (Perros et al. 2014)**

Benign nodule	Malignant nodule: Papillary/medullary	Follicular lesion
Spongiform/honeycomb	Solid and hypoechoic	Hyperechoic/ homogeneous/halo benign
Purely cystic	Irregular margin	Hypoechogenicity/loss of halo suspicious
Egg shell calcification	Intranodular vascularity	
Iso/hyper echoic (hypoechoic halo)	Absence of halo	
Peripheral vascularity	Taller than wide	
	Microcalcifications	

717

718 **Table 3: Summary of studies investigating serum TSH and thyroid cancer diagnosis**

Reference	Journal	Number of patients	Country of study	Significant findings	Serum TSH 'cut off' value
(Boelaert et al. 2006)	J Clin Endocrinol Metab	1,500	UK	Serum TSH is an independent predictor of malignancy in thyroid nodules. Risk of thyroid cancer rises in parallel with serum TSH in the normal range.	0.9 – 5.5 mIU/litre
(Polyzos, et al. 2008)	J Cancer Res Clin Oncol	565	Greece	Higher rates of thyroid malignancy in patients with TSH in upper tertile of normal range.	1.5 – 4 mIU/l
(Haymart et al. 2008)	JCEM	843	US	Higher serum TSH is associated with advanced stage-differentiated thyroid cancer.	1.4 – 4.9 mIU/litre
(Jonklaas et al. 2008)	Thyroid	50	US	Higher TSH is associated with increased likelihood of diagnosis of thyroid cancer. Patients with thyroid cancer have lower serum total T3 concentrations.	1.8 – 5.5 mIU/L
(Haymart et al. 2009)	Clinical Endocrinology	1361	US	Risk of thyroid cancer increases with increased TSH independent of age.	No cut off value
(Fiore et al. 2009)	Endocrine Related Cancer	10,178	Italy	Higher TSH in patients with T3-T4 disease and in those with lymph node metastases. Autonomously functioning thyroid nodules are less likely to be malignant.	1.6 – 3.4 mU/ml
(Gerschpacher, et al. 2010)	Thyroid	87	Austria	TSH may play a role in thyroid cancer progression rather than oncogenesis.	
(Zafon, et al. 2012)	Journal of Thyroid Research	386	Spain	TSH levels are higher in patients with DTC. Increment in tumour size rises in parallel with incremental rise in TSH.	No cut off value
(Kim et al. 2013)	Clinical Endocrinology	1759	South Korea	High TSH level within the normal range is an independent risk factor for DTC and can be used as a diagnostic adjunct.	2.31 - 4.80 mIU/l
(Sohn et al. 2014)	Head and Neck	3791	South Korea	Serum TSH may not be useful for clinical risk assessment of small thyroid nodules.	2.13 – 4.2 mU/L
(Figuera et al. 2015)	Endokrynol Pol	622	Brazil	Risk of carcinoma in nodular disease rises in parallel with serum TSH.	above 1.64 mU/L
(Khan, et al. 2016)	Asian Pac J Cancer Prev	73	Pakistan	Higher pre-surgical TSH correlates with thyroid cancer.	
(Shi et al. 2016)	Endocrine Journal	1870	China	Raised TSH is related to cancer stage but not likely to be related to initiation.	Meta-analysis

719

720

721

722

723 **Table 4: Table summarising studies investigating TSH and papillary microcarcinoma**

Reference	Journal	Number of patients	Country of study	Significant findings
(Haymart et al. 2008)	JCEM	843	US	Escalating cancer risk with higher TSH level in microcarcinomas. More research warranted.
(Moon et al. 2012)	Head and Neck	483	South Korea	TSH measurement in the context of thyroid micronodule can exclude cancer
(Shi, et al. 2012)	Endocr J	1870	China	TSH does not correlate with microcarcinoma presence and therefore TSH can only be linked with progression of carcinoma
(Negro et al. 2013)	Endocrine Practice	205	Italy	No difference in serum TSH between papillary microcarcinoma group compared to controls
(Sohn et al. 2014)	Head and Neck	3791	South Korea	Serum TSH may not be useful for clinical risk assessment of small thyroid nodules
(Jiao and Zhou 2015)	Zhonghua Yi Xue Za Zhi	365	China	TSH is probably associated with oncogenesis in papillary microcarcinoma (PTMC) although it may only be involved in growth of pre-existing PTMC

724